Digoxin for reduction of circulating tumor cell cluster size in metastatic breast cancer: a proof-of-concept trial
University of Basel · University Hospital of Basel · +8 more institutions
Abstract
Abstract The presence of circulating tumor cell (CTC) clusters is associated with disease progression and reduced survival in a variety of cancer types. In breast cancer, preclinical studies showed that inhibitors of the Na + /K + ATPase suppress CTC clusters and block metastasis. Here we conducted a prospective, open-label, proof-of-concept study in women with metastatic breast cancer, where the primary objective was to determine whether treatment with the Na + /K + ATPase inhibitor digoxin could reduce mean CTC cluster size. An analysis of nine patients treated daily with a maintenance digoxin dose (0.7–1.4 ng ml −1 serum level) revealed a mean cluster size reduction of −2.2 cells per cluster upon treatment…
Citation impact
- FWCI
- 39.80
- Percentile
- 100%
- References
- 17
Authors
24- CKChristian Kurzeder
University of Basel, University Hospital of Basel
- BDBich Doan Nguyen-Sträuli
University of Basel, University of Zurich, University Hospital of Basel, University Hospital of Zurich, École Polytechnique Fédérale de Lausanne
- IKIlona Krol
École Polytechnique Fédérale de Lausanne
- ARAlexander Ring
University of Zurich, University Hospital of Zurich, École Polytechnique Fédérale de Lausanne
- FCFrancesc Castro-Giner
École Polytechnique Fédérale de Lausanne
Topics & keywords
- Digoxin
- Breast cancer
- Clinical endpoint
- Internal medicine
- Medicine
- Oncology
- Cancer
- Metastatic breast cancer
- Good health and well-being